Basepaws Acquisition: Exploring Biotech Beyond Human Health

While much of the biotech community focuses on the incredible potential it has to transform healthcare and medicine, the discoveries scientists are making today have applications far beyond human health. Enter Basepaws, a pet health and genetics company using the latest innovations to revolutionise the well-being of humanity’s beloved feline companions. 

Basepaws uses scientific discoveries in genetics and microbiome research to offer genetic testing kits for cats. The three Basepaws tests look at breed and health, dental health, and a complete genome sequence. Owners send cell samples from their cats that Basepaws scientists compare to the whole cat genome and Basepaws genome database to identify vulnerability to diseases and breed characteristics. Cat owners can use these reports to understand their pets’ health and wellbeing and proactively approach any treatment. The reports are veterinarian-approved, supported by Basepaws’s Veterinary Advisory Board of 14 veterinary experts.  

The company has flourished and secured additional deals, including from “sharks” Kevin O’Leary and Robert Herjavec on the US television program Shark Tank. Now, it’s time for their next step.  

Today, we are thrilled to share an exciting announcement for the biotech space: Basepaws has been acquired by Zoetis, the world’s leading animal health company. Zoetis will benefit from Basepaws’ expansive database of feline genetics, helping to expand their R&D in feline health and inspire future innovations. 

LongeVC’s Managing Partner Garri Zmudze previously invested in Basepaws during its pre-seed stage as he was excited about the work the company was doing to apply cutting-edge science to a typically underexplored area of biotech. A seasoned angel investor, Garri also supported AI drug discovery firm Insilico Medicine in its pre-seed stage. Insilico Medicine is currently leading the world’s first-in-human trial of an AI-discovered drug with Series D funding support from top firms like Warburg Pincus, B Capital Group, Qiming Venture Partners, BOLD Capital Partners, Pavilion Capital and more. 

As a Managing Partner of LongeVC, Garri brings his investing expertise to enhance LongeVC’s vetting process, helping to ensure potential portfolio companies have the characteristics needed to succeed in the fast-paced world of biotech. Garri noted, “Basepaws is changing the way we view the health of our pets. Biotech applications go far beyond human medical treatments, and Basepaws has shown that there is a market appetite for such innovations. Congratulations to the Basepaws team for this achievement. I look forward to seeing more from these visionary minds in the future.”

From the moment we heard about Basepaws, the LongeVC team was excited about its potential for transforming biotech. We wish the Basepaws team all the best and continued success!